![\"Human](\"https:\/\/findpeptideclinics.com\/blog\/wp-content\/uploads\/charts\/label_warnings_evidence.png\")
The study started with friends, not with a hypothesis. Giorgia Rutigliani, a PhD candidate in the nutrition science department at Purdue, watched colleagues and friends on GLP-1 medications report the same strange collection of changes. Food tasted different. Cravings went quiet. A persistent, intrusive background chatter about eating, the thing patients call food noise, faded to nothing.<\/p>\n
She took the question to her supervisor, Richard Mattes, a distinguished professor at Purdue who has spent a career on taste, smell and ingestive behavior. The big trials had already printed their headline numbers, the percentage of body weight lost, the drop in energy intake. The question of why people were eating less went unasked. Was food less rewarding? Were they less hungry? Or had something upstream in attention and motivation switched off?<\/p>\n
That gap is where this study lives. It appeared in Physiology & Behavior on August 25, 2026, under the title “The effects of glucagon-like peptide-1 receptor agonists on chemosensory function and ingestive behavior,” and it puts GLP-1 users through laboratory taste and smell testing alongside questionnaires on food noise, craving, cue responsivity and food reward.<\/p>\n
An anecdote is how a question gets asked. It is a poor way to answer one.<\/p>\n
The Design: 27, 25, 27 And A Lab That Would Not Take A Story As Data<\/h2>\n
The team recruited 79 adults with obesity, aged 18 to 65, and sorted them by how long they had been on a GLP-1. Twenty-seven were eligible for treatment and had not begun. Twenty-five had been on a GLP-1 for about a month. Twenty-seven had been on one for about six months.<\/p>\n
The registry entry, NCT07611201<\/a>, lists 90 people enrolled and a completion date of May 4, 2026, with Purdue University as the sponsor and no drug company listed as a collaborator. The published analysis covers the 79 who finished the full battery.<\/p>\n Each participant came in alone, because sensory testing in a room full of other people measures the room. They tasted solutions and reported the weakest concentration they could detect. They rated intensity. They built their preferred levels of sweet, salty, sour, bitter and fatty. They chewed fat strips, took an olfactory test, and had saliva weighed before and after exposure to a food cue. The questionnaires covered food noise, cue responsivity, cravings and food reward, and dietary intake came from 24-hour recalls.<\/p>\n This is a cross-sectional study. It compared three groups at a single point in time. No randomization, no medication handed out, no follow-up.<\/p>\n No manufacturer paid for it. Keep that in your pocket while you read the rest.<\/p>\n The sensory side came up close to empty, with one exception. Sweet taste detection thresholds differed across the groups (p=0.001), and both user groups needed more sugar than the pre-use group to register sweetness at all (one month, p=0.0078; six months, p=0.0024).<\/p>\n Read that slowly, because it flips easily. A higher detection threshold means lower sensitivity. GLP-1 users required more sugar in solution to notice sweet. Salty, sour and bitter moved in the same direction, toward lower sensitivity, without reaching significance. Intensity ratings, how much people liked the tested solutions, smell performance and chemesthesis all came back largely unchanged, with one fat-intensity rating at a medium concentration of linoleic acid as the lone stray.<\/p>\n The host of the interview that surfaced this work told Rutigliani the sweet finding contradicted his own experience with the drugs, and he is not alone in that. Patients describe desserts turning cloying after two bites. The data says the detection threshold moved and the pleasure ratings did not. That is a narrower claim than either side of the argument usually makes.<\/p>\n The menu did not change. The meter that reads it moved slightly.<\/p>\n The behavioral measures carried the signal. Food Noise Questionnaire scores were lower in six-month GLP-1 users than in the pre-use group (P=.026). Six-month users also scored lower on cue responsivity, food craving and food reward, and reported lower energy intake. Protein intake did not differ, which undercuts the assumption that the weight change is people losing muscle by accident.<\/p>\n The distinction the researchers built the study around is liking against wanting. Liking is what you feel with food in your mouth. Wanting is what pulls you toward the kitchen at 10pm. The published results put liking near baseline and wanting measurably lower, which matches what patients have reported for three years while the clinical trial literature stayed focused on kilograms.<\/p>\n One caveat belongs in the same breath. The one-month group did not produce the same significant food noise drop as the six-month group in the published summary. Timing matters, and a month is not a fair test of anything.<\/p>\n The craving did not get argued down. It got quieter.<\/p>\n Mattes is the corresponding author and the senior scientist here, with a long publication record in taste and ingestive behavior research. His conflict-of-interest statement lists consulting, advisory work or research funding from the Grain Foods Foundation, the Almond Board of California, Chobani, General Mills and its Bell Institute of Health and Nutrition, and Mars Food, plus travel and participation support from a longer list that includes Nestl\u00e9 Foods, Tate & Lyle and the National Confectioners Association. Rutigliani declares no competing interests.<\/p>\n Put the disclosure beside the data and keep moving. Food industry money in a nutrition lab deserves to be visible, and here it is visible. The registry shows no maker of semaglutide or tirzepatide paying for any of it.<\/p>\n Two facts, one sentence. The companies selling the drugs did not buy this study, and the senior author takes food industry money.<\/p>\n A cross-sectional comparison can show association. It cannot show cause. The paper states this, and anyone quoting the paper should state it too.<\/p>\n So here is the honest list of what the study does not say. It does not say a GLP-1 caused the drop in food noise, because people who stay on a drug for six months differ from people who quit at week three, and that difference alone can move a questionnaire score. It does not compare semaglutide against tirzepatide, because the team did not stratify by drug, which leaves the popular claim that the GIP component is what silences food noise sitting where it belongs, as a hypothesis. It says nothing about what happens after you stop, and the return of food noise on discontinuation is widely reported but untested here. It covers six months, 79 people, one corner of Indiana.<\/p>\n A snapshot is not a forecast. It is a frame, and a useful one.<\/p>\n Three things to carry into a consult. None of them is dosing advice.<\/p>\n Ask what the plan is for food noise, not only for pounds. This study treats food noise as a measurable endpoint with a questionnaire behind it, which gives you something to track besides the scale.<\/p>\n Ask whether the product is FDA-approved or compounded. Branded tirzepatide and semaglutide went through FDA review. Compounded versions did not, and the FDA says so on its own compounding page<\/a>: “Compounded drugs are not FDA-approved,” and the agency does not verify their safety, effectiveness or quality before marketing. A clinic or pharmacy that blurs that line is telling you something about itself.<\/p>\n Ask what this paper tested. The registry describes participants taking a GLP-1 as part of their regular medical care. No compounded product was tested, so no claim about compounded products can be built on this study.<\/p>\n Search for peptide clinics and you will find a wide market and a thin evidence base on the marketing side. This paper is the other kind of evidence. Small, careful, published, and specific about its own limits.<\/p>\n Ask for the citation. A clinic with a real clinical partner will have one.<\/p>\n Which of these compounds may a compounding pharmacy lawfully prepare, and in which state? The peptide regulatory status tracker<\/a> sets out FDA status compound by compound, with dates and sources.<\/p>\n No. It found one significant sensory difference, in sweet taste detection, and no significant changes in smell, taste intensity, how much people liked the tested solutions, or chemesthesis. The larger changes appeared in questionnaire measures of food noise, craving and food reward.<\/p>\n It began as patient language and moved into the literature. A 2023 paper in Nutrients, “What Is Food Noise? A Conceptual Model of Food Cue Reactivity”<\/a>, describes it as the rumination and preoccupation with food that GLP-1 users report fading. The Purdue study measured it with the Food Noise Questionnaire.<\/p>\n Unknown from this study. The team did not stratify participants by medication, so a difference between a GLP-1 and a dual GIP\/GLP-1 agonist remains untested here.<\/p>\n Yes, as a symptom worth tracking. Bring the paper. The useful clinical question is whether your appetite control is working at your current dose, and that conversation belongs with a licensed prescriber who knows your history.<\/p>\n The registry lists Purdue University as the sponsor with no collaborators. The senior author discloses food industry funding and advisory relationships. The first author declares no competing interests.<\/p>\n Sources: PubMed<\/a>, Physiology & Behavior<\/a>, ClinicalTrials.gov<\/a>, FDA<\/a>, Nutrients<\/a>, The Downsized<\/a>.<\/p>\nSweet Taste: The One Sensory Dial That Moved<\/h2>\n
Food Noise: The Finding That Matters If You Are Deciding Whether To Start<\/h2>\n
Richard Mattes: The Name On The Paper And The Disclosures Beside It<\/h2>\n
Cross-Sectional: The Word In The Methods That Should Slow You Down<\/h2>\n
What This Means If You Are Shopping For Treatment Right Now<\/h2>\n
Frequently Asked Questions<\/h2>\n
Did this study prove that GLP-1s change how food tastes?<\/h3>\n
Is “food noise” a real medical term?<\/h3>\n
Does this mean tirzepatide quiets food noise better than semaglutide?<\/h3>\n
Should I ask my clinician about food noise?<\/h3>\n
Who paid for this study?<\/h3>\n